A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome

By sjmartinez • March 29, 2025

Garcia-Manero G, Gaddh M, Platzbecker U, Lindsley RC, Larson SM, Chevassut T, Fenaux P, Komrokji R, Lyons R, Al-Kali A, Jiang Y, Bothos J, Townsley DM, Zeidan AM. A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome. Ann Hematol. 2025 Mar 28. doi: 10.1007/s00277-024-06081-4. Epub ahead of print. PMID: 40153010.

Tags: Acute myeloid leukemia, CTLA-4, durvalumab, First-in-human, Hematology/Oncology, MDS, PD-L1, Publications

Bone Marrow Failure in Prostate Cancer: A Rare Case Initially Disguised as Thrombotic Thrombocytopenic Purpura

Dommaraju SR, Shodiya M, Henick K. Bone Marrow Failure in Prostate Cancer: A Rare Case Initially Disguised as Thrombotic Thrombocytopenic Purpura. Cureus. 2025 Mar 18;17(3):e80781.[...]

Development of a GPT-4-Powered Virtual Simulated Patient and Communication Training Platform for Medical Students to Practice Discussing Abnormal Mammogram Results With Patients: Multiphase Study

Weisman D, Sugarman A, Huang YM, Gelberg L, Ganz PA, Comulada WS. Development of a GPT-4-Powered Virtual Simulated Patient and Communication Training Platform for Medical[...]

Noninvasive Assessment of β-Secretase Activity Through Click Chemistry-Mediated Enrichment of Neuronal Extracellular Vesicles to Detect Alzheimer’s Disease

Kim H, Lee J, Qian A, Ji YR, Zhang R, Hu Q, Williams CK, Chuang HY, Smalley MD, Xu Y, Gao L, Mayo MC, Zhang[...]